599 related articles for article (PubMed ID: 27127191)
1. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy of cancer utilizing genetically engineered lymphocytes.
Ikeda H; Shiku H
Cancer Immunol Immunother; 2015 Jul; 64(7):903-9. PubMed ID: 26041411
[TBL] [Abstract][Full Text] [Related]
3. The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients.
Arnaud M; Bobisse S; Chiffelle J; Harari A
Front Immunol; 2021; 12():701636. PubMed ID: 34394096
[TBL] [Abstract][Full Text] [Related]
4. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
5. The recent advancement of TCR-T cell therapies for cancer treatment.
Zhao X; Shao S; Hu L
Acta Biochim Biophys Sin (Shanghai); 2024 May; 56(5):663-674. PubMed ID: 38557898
[TBL] [Abstract][Full Text] [Related]
6. Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.
Udyavar A; Geiger TL
Arch Immunol Ther Exp (Warsz); 2010 Oct; 58(5):335-46. PubMed ID: 20680493
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.
Foster JB; Barrett DM; Karikó K
Mol Ther; 2019 Apr; 27(4):747-756. PubMed ID: 30819612
[TBL] [Abstract][Full Text] [Related]
8. Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.
Xin G; Schauder DM; Zander R; Cui W
Immunotherapy; 2017 Sep; 9(10):837-849. PubMed ID: 28877635
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell transfer as personalized immunotherapy for human cancer.
Rosenberg SA; Restifo NP
Science; 2015 Apr; 348(6230):62-8. PubMed ID: 25838374
[TBL] [Abstract][Full Text] [Related]
10. Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
Ren YB; Sun SJ; Han SY
Curr Pharm Des; 2018; 24(1):78-83. PubMed ID: 29283058
[TBL] [Abstract][Full Text] [Related]
11. Re-adapting T cells for cancer therapy: from mouse models to clinical trials.
Stromnes IM; Schmitt TM; Chapuis AG; Hingorani SR; Greenberg PD
Immunol Rev; 2014 Jan; 257(1):145-64. PubMed ID: 24329795
[TBL] [Abstract][Full Text] [Related]
12. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.
Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA
Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
[TBL] [Abstract][Full Text] [Related]
14. The Anticancer Potential of T Cell Receptor-Engineered T Cells.
Ecsedi M; McAfee MS; Chapuis AG
Trends Cancer; 2021 Jan; 7(1):48-56. PubMed ID: 32988787
[TBL] [Abstract][Full Text] [Related]
15. Targeting T cell metabolism for immunotherapy.
Gao J; Liu Y; Wei J; Jiang L; Mao J; Chang CH; Wu D
J Leukoc Biol; 2021 Dec; 110(6):1081-1090. PubMed ID: 34779530
[TBL] [Abstract][Full Text] [Related]
16. Adoptive T cell therapy of solid cancers.
Knutson KL; Wagner W; Disis ML
Cancer Immunol Immunother; 2006 Jan; 55(1):96-103. PubMed ID: 15891880
[TBL] [Abstract][Full Text] [Related]
17. An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
Chen L; Dong L; Ma Y; Wang J; Qiao D; Tian G; Wang M
BMC Immunol; 2021 Sep; 22(1):65. PubMed ID: 34583647
[TBL] [Abstract][Full Text] [Related]
18. New emerging targets in cancer immunotherapy: the role of neoantigens.
De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J
ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031
[TBL] [Abstract][Full Text] [Related]
19. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.
Li X; Zhu Y; Yi J; Deng Y; Lei B; Ren H
J Leukoc Biol; 2024 Apr; 115(5):866-881. PubMed ID: 37949484
[TBL] [Abstract][Full Text] [Related]
20. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.
Trajanoski Z; Maccalli C; Mennonna D; Casorati G; Parmiani G; Dellabona P
Cancer Immunol Immunother; 2015 Jan; 64(1):99-104. PubMed ID: 25164877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
